Incidence of Acute Intestinal Graft-Versus-Host Disease and Survival After Allogeneic Stem Cell Transplantation in the 2 Antibiotic Groups
| . | Permissive . | Restrictive . | P (Chi-square Test) . |
|---|---|---|---|
| GI GvHD | 32.7% (33/101) | 33.3% (29/87) | NS |
| Severe GI GvHD | |||
| Stage 2–4 | 15.8% (16/101) | 8.0% (7/87) | .10 |
| Overall survival | 57.4% (58/101) | 64.4% (56/87) | NS |
| TRM | 22.8% (23/101) | 14.9% (13/87) | .17 |
| . | Permissive . | Restrictive . | P (Chi-square Test) . |
|---|---|---|---|
| GI GvHD | 32.7% (33/101) | 33.3% (29/87) | NS |
| Severe GI GvHD | |||
| Stage 2–4 | 15.8% (16/101) | 8.0% (7/87) | .10 |
| Overall survival | 57.4% (58/101) | 64.4% (56/87) | NS |
| TRM | 22.8% (23/101) | 14.9% (13/87) | .17 |
Abbreviations: GI, gastrointestinal; GvHD, graft-versus-host disease; NS, not significant; TRM, transplant-related mortality.
Incidence of Acute Intestinal Graft-Versus-Host Disease and Survival After Allogeneic Stem Cell Transplantation in the 2 Antibiotic Groups
| . | Permissive . | Restrictive . | P (Chi-square Test) . |
|---|---|---|---|
| GI GvHD | 32.7% (33/101) | 33.3% (29/87) | NS |
| Severe GI GvHD | |||
| Stage 2–4 | 15.8% (16/101) | 8.0% (7/87) | .10 |
| Overall survival | 57.4% (58/101) | 64.4% (56/87) | NS |
| TRM | 22.8% (23/101) | 14.9% (13/87) | .17 |
| . | Permissive . | Restrictive . | P (Chi-square Test) . |
|---|---|---|---|
| GI GvHD | 32.7% (33/101) | 33.3% (29/87) | NS |
| Severe GI GvHD | |||
| Stage 2–4 | 15.8% (16/101) | 8.0% (7/87) | .10 |
| Overall survival | 57.4% (58/101) | 64.4% (56/87) | NS |
| TRM | 22.8% (23/101) | 14.9% (13/87) | .17 |
Abbreviations: GI, gastrointestinal; GvHD, graft-versus-host disease; NS, not significant; TRM, transplant-related mortality.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
